Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Merck's Keytruda Misses One of Two Goals in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints. It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.
Pfizer/Merck KGaA's Bavencio Positive in Bladder Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA's Bavencio meets the primary goal in a late-stage study evaluating it as a first-line maintenance therapy for metastatic urothelial carcinoma, a form of bladder cancer.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $38.87, marking a -0.15% move from the previous day.
Aerie's (AERI) Application for Roclanda Accepted in Europe
by Zacks Equity Research
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
Horizon Therapeutics' Stock Up in a Year on Pipeline Progress
by Zacks Equity Research
Horizon Therapeutics' (HZNP) shares have risen in the past year owing to the development of its pipeline candidates.
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
by Zacks Equity Research
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
The Zacks Analyst Blog Highlights: Pfizer, BP, Fidelity National Information Services, Deere & Company and Equity Residential
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BP, Fidelity National Information Services, Deere & Company and Equity Residential
3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020
by Zacks Equity Research
Here are three reasons, which investors may consider while investing in Lilly's (LLY) stock.
The Zacks Analyst Blog Highlights: Exxon Mobil, Verizon, Chevron, Pfizer and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Verizon, Chevron, Pfizer and 3M
Top Stock Reports for Pfizer, BP & Fidelity National Information Services
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), BP p.l.c. (BP) and Fidelity National Information Services (FIS).
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $39.16, marking a +0.64% move from the previous day.
AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza becomes the first PARP inhibitor to get approval for treating pancreatic cancer in the United States.
5 Dogs of the Dow for 2020
by Tirthankar Chakraborty
It may be all bark and no bite for Dogs of the Dow in 2019. But 2020 holds promise for them.
Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline
by Zacks Equity Research
Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.
Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?
by Zacks Equity Research
As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.
Pfizer (PFE) Sees a Difficult 2019: Can it Rebound in 2020?
by Zacks Equity Research
Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.
Epizyme (EPZM) Shares Soar on Lead Candidate's Progress
by Zacks Equity Research
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $39.32 in the latest trading session, marking a +0.23% move from the prior day.
GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA
by Zacks Equity Research
GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.
Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication
by Zacks Equity Research
The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs
by Kinjel Shah
Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
Pfizer's Braftovi sNDA Accepted by FDA for Priority Review
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $38.90 in the latest trading session, marking a -0.61% move from the prior day.